Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian C van Capelleveen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Lipidology|September 26, 2014
Inhibition of ApoCIII: the next PCSK9?Sophie J Bernelot Moens, Julian C van Capelleveen, Erik S G Stroes
Journal of Lipid Research|December 6, 2015
Current therapies for lowering lipoprotein (a)Julian C van Capelleveen, Fleur M van der Valk, Erik S G Stroes
Journal of Clinical Lipidology|June 16, 2015
Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiencyJulian C van Capelleveen, Ruud S Kootte, G Kees Hovingh, et al.
Circulation Research|January 4, 2014
Novel therapies focused on the high-density lipoprotein particleJulian C van Capelleveen, H Bryan Brewer, John J P Kastelein, et al.
Current Atherosclerosis Reports|April 18, 2013
Genetics of HDL-C: a causal link to atherosclerosis?Julian C van Capelleveen, Andrea E Bochem, M Mahdi Motazacker, et al.
Journal of Clinical Lipidology|September 29, 2016
Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclassesJulian C van Capelleveen, John J P Kastelein, Aeilko H Zwinderman, et al.
Journal of the American Society of Nephrology : JASN|November 2, 2016
Arterial and Cellular Inflammation in Patients with CKDSophie J Bernelot Moens, Simone L Verweij, Fleur M van der Valk, et al.
Journal of Clinical Lipidology|September 26, 2018
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population studyJulian C van Capelleveen, Sang-Rok Lee, Rutger Verbeek, et al.
Atherosclerosis|April 23, 2016
A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacityMahdi M Motazacker, Juho Pirhonen, Julian C van Capelleveen, et al.
Journal of Clinical Lipidology|July 5, 2020
Genetic variants in SUSD2 are associated with the risk of ischemic heart diseaseCaroline S Bruikman, Nawar Dalila, Julian C van Capelleveen, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Lipidology|September 26, 2014
Inhibition of ApoCIII: the next PCSK9?Sophie J Bernelot Moens, Julian C van Capelleveen, Erik S G Stroes
Journal of Lipid Research|December 6, 2015
Current therapies for lowering lipoprotein (a)Julian C van Capelleveen, Fleur M van der Valk, Erik S G Stroes
Journal of Clinical Lipidology|June 16, 2015
Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiencyJulian C van Capelleveen, Ruud S Kootte, G Kees Hovingh, et al.
Circulation Research|January 4, 2014
Novel therapies focused on the high-density lipoprotein particleJulian C van Capelleveen, H Bryan Brewer, John J P Kastelein, et al.
Current Atherosclerosis Reports|April 18, 2013
Genetics of HDL-C: a causal link to atherosclerosis?Julian C van Capelleveen, Andrea E Bochem, M Mahdi Motazacker, et al.
Journal of Clinical Lipidology|September 29, 2016
Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclassesJulian C van Capelleveen, John J P Kastelein, Aeilko H Zwinderman, et al.
Journal of the American Society of Nephrology : JASN|November 2, 2016
Arterial and Cellular Inflammation in Patients with CKDSophie J Bernelot Moens, Simone L Verweij, Fleur M van der Valk, et al.
Journal of Clinical Lipidology|September 26, 2018
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population studyJulian C van Capelleveen, Sang-Rok Lee, Rutger Verbeek, et al.
Atherosclerosis|April 23, 2016
A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacityMahdi M Motazacker, Juho Pirhonen, Julian C van Capelleveen, et al.
Journal of Clinical Lipidology|July 5, 2020
Genetic variants in SUSD2 are associated with the risk of ischemic heart diseaseCaroline S Bruikman, Nawar Dalila, Julian C van Capelleveen, et al.
Pageof 2